Senju Pharmaceutical Beijing Co. Ltd., part of Senju Pharmaceutical Co., Ltd., is a company headquartered in Beijing, China, that manufactures and distributes pharmaceuticals.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient-friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept while establishing R&D collaborations with select partners to improve products in their pipelines.

Engages in creating molecular diagnostics for sepsis

InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The company's product portfolio utilizes InSite Vision's proven DuraSite(R) bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite(R) (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Inspire Pharmaceuticals, and Besivance(TM) (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch & Lomb and their partner Pfizer Inc. InSite Vision's clinical-stage ophthalmic product pipeline includes AzaSite Plus(TM) (ISV-502) and ISV-305 for the treatment of eye infections, ISV-303 for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease.

Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert in 1950 and headquartered in Irvine, CA.

Part of Bausch Health Cos., Inc., Bausch & Lomb Pharma Holdings Corp. is an American company that manufactures and markets pharmaceutical products.

Ocugen is a clinical-stage biopharmaceutical company focused on discoverinOcugen Inc is a clinical-stage biopharmaceutical business focused on discovering, developing, and commercializing gene treatments to cure blinding illnesses, as well as developing a COVID-19 vaccine to save lives. The biologic product candidate aims to provide better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy using the breakthrough modifier gene therapy platform.

Guangzhou Aobo Pharmaceutical Technology Co., Ltd., established on 2016-12-19, Business scope includes medical research and experimental development;drug development;Biotechnology Development Services;Biotechnology Extension Services;Biotechnology Consulting,communication service;Commodity wholesale trade(Except for licensed and approved products);Department store retail(except food retail);Information Technology Consulting Services;Commodity Information Consulting Service;Medical supplies and equipment retail(Does not contain drugs and medical devices);Wholesale of cosmetics and hygiene products;Retailing of cosmetics and hygiene products;ticket service;Food Science and Technology Research Services;Chemical Reagent and Auxiliary Manufacturing(Monitor Chemicals,Excluding hazardous chemicals);Market Research Services;Conference and Exhibition Services;Company etiquette service;Large-scale event organization and planning services(Large-scale events refer to evening parties,sports meeting,celebration,Art and Modeling Contest,Arts festival,Film festivals and charity performances,Exhibition etc.,Activities that require special approval should be operated after obtaining approval);Investment Advisory Services;Operation of non-licensed medical devices;medical diagnosis,Monitoring and treatment equipment retail;Licensed medical device business;medical diagnosis,Monitoring and treatment equipment wholesale;

Rayner Surgical, Inc., a subsidiary of Rayner Surgical Group Ltd., is an American company located in New York, NY, that manufactures and sells surgical & optical products. It was founded in 2017. Timothy James Clover has been the CEO since 2014.

Hefei Huawei Pharmaceutical Co., Ltd., established on 1995-01-28, The business scope includes granules,Capsules,tablet,Solution(Including external use),Eye drop production(Operate within the validity period of the drug production license);Health food production and sales;anti-(suppress)Bacterial preparation(liquid,gel)(purify),liquid disinfectant(purify)production and sales of;one type,Production and sales of Class II medical equipment;Biotechnology,drug development,Technology Development and Transfer,Technical Consulting and Services;Business Management Consulting;Market Consulting,Promotion service;Meeting,Exhibition service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Zhongshan Ophthalmic Center, part of Sun Yat-Sen University, is a Chinese company located in Guangzhou that operates hospitals.

Guangdong Hongying Technology Co., Ltd., established on 2000-03-24, Business scope includes research and development:natural animal and plant extracts,Pharmaceutical Intermediates,food,Health products;pharmaceutical production,Sales;Import and export,Technology Import and Export;Manufacture and sales of plastic products;optical fiber,fiber optic cable,electric wire,cable,Conductors and related materials and accessories,active device,Passive devices and other optoelectronic devices,communication device(Does not include satellite TV broadcast ground receiving equipment,launch facility),Sales of power transmission and distribution and control equipment;fiber optic cable,electric wire,cable,Cable monitoring management system and network engineering technology development and related technical services;Industrial Investment;Development of communication and network information products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

IBI is developing a broad portfolio of clinically superior proprietary products, based on its Verisome® drug delivery technology. The company’s initial focus is on its pipeline of reduced-risk, low-cost development programs targeting every major ophthalmic market. IBI’s lead portfolio product, IBI-10090 completed enrollment in its pivotal phase 2/3 clinical trial, in December 2012. An NDA is planned for late 2013. It was founded in 2004 and headquartered in Sunnyvale, California.

Shang Hai Bao Ji Yao Ye Gu Fen You Xian Gong Si, established on 2019-12-16, Business scope includes licensed projects:pharmaceutical production(Steamed Chinese Herbal Pieces,saute,broil,The application of calcining and other processing technologies and the production of secret prescription products of Chinese patent medicines);Pharmaceutical commissioned production(Steamed Chinese Herbal Pieces,saute,broil,The application of calcining and other processing technologies and the production of secret prescription products of Chinese patent medicines);Drug import and export;Drug Wholesale;Drug retail.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Import and export;Technology Import and Export;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Japan Tobacco, Inc. engages in the manufacture and sale of tobacco, pharmaceutical and processed food products. It operates through the following divisions: Japanese Domestic Tobacco, International Tobacco, Pharmaceutical, and Processed Food. The Japanese Domestic segment deals with the production and sale of tobacco products in domestic areas. The International Tobacco segment manufactures and markets tobacco products worldwide. The Pharmaceutical segment develops, manufactures, and sells prescription drugs. The Processed Food segment offers processed food, bakery products and seasonings. The company was founded on April 1, 1985 and is headquartered in Tokyo, Japan.

Fuxiang Sitai Medical Technology (Suzhou) Co., Ltd., established on 2020-10-21, Business scope includes licensed projects:Production of Class III Medical Devices;Class III medical device business;Production of Class II Medical Devices;food production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Sales of Class II Medical Devices;Production of Class I Medical Devices;Sales of Class I Medical Devices;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Personal Hygiene Sales;Cosmetics Retail;3DPrint base material sales;3Dprint service;General machinery and equipment installation services;market survey(Does not include foreign investigations);Conference and Exhibition Services(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Menicon creates contact lenses. In response to consumer demand, they increase the range of products and services available. Animal ophthalmic care uses the same technology that was developed for contact lenses for people. They aid in the growth of veterinary ophthalmology in cooperation with veterinarians. Use the technology that has been developed for the creation of care and contact lenses in the environmental business sector.